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Abstract 
Background: Metabolic syndrome is characterized by macrophage infiltration and inflammatory responses—
metaflammation in adipose tissue. IL-6 and IL-1β could mediate the inflammatory responses in macrophage 
stimulated-preadipocytes by modulating MAPK and NF-κB pathways. To test this hypothesis we used antibodies to 
block IL-6 and IL-1β action in macrophage conditioned medium (MacCM)-stimulated human white preadipocytes. 
Moreover, as interventions that prevent this could potentially be used to treat or prevent metabolic syndrome, and 
1α,25(OH)2D3 has previously been reported to exert an anti-inflammatory action on macrophage-stimulated adipo-
cytes, in this study we also investigated whether 1α,25(OH)2D3 could attenuate inflammatory responses in MacCM-
stimulated preadipocytes, and explored the potential anti-inflammatory mechanisms.
Methods: Human white preadipocytes were cultured with 25% MacCM for 24 h to elicit inflammatory responses. 
This was confirmed by measuring the concentrations and mRNA levels of major pro-inflammatory factors [IL-1β, IL-6, 
IL-8, monocyte chemoattractant protein (MCP)-1 and regulated on activation, normal T cell expressed and secreted 
(RANTES)] by ELISA and qPCR, respectively. IL-6 and IL-1β actions were blocked using IL-6 antibody (300 ng/ml) and 
IL-1β antibody (15 μg/ml), respectively. Potential anti-inflammatory effects of 1α,25(OH)2D3 were investigated by 
pre-treatment and treatment of 1α,25(OH)2D3 (0.01 to 10 nM) for 48 h in MacCM-stimulated preadipocytes. In parallel, 
western blotting was used to determine inflammatory signaling molecules including relA of the NF-κB pathway and 
p44/42 MAPK modified during these processes.
Results: MacCM enhanced the secretion and gene expression of IL-1β, IL-6, IL-8, MCP-1 and RANTES by increasing the 
phosphorylation levels of relA and p44/42 MAPK in preadipocytes, whereas blocking IL-6 and IL-1β action inhibited 
the inflammatory responses by decreasing p44/42 MAPK and relA phosphorylation, respectively. Furthermore, 10 nM 
of 1α,25(OH)2D3 generally inhibited the IL-6 and IL-1β-mediated inflammatory responses, and reduced both p44/42 
MAPK and relA phosphorylation in MacCM-stimulated preadipocytes.
Conclusions: 1α,25(OH)2D3 attenuates IL-6 and IL-1β-mediated inflammatory responses, probably by inhibiting 
p44/42 MAPK and relA phosphorylation in MacCM-stimulated human white preadipocytes.
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Background
Metabolic syndrome is a clustering of clinical findings 
consisting of abdominal obesity, high glucose, high tri-
glycerides, low high-density lipoprotein cholesterol lev-
els, and hypertension [1]. Metaflammation in adipose 
tissue, characterized by infiltration of macrophages, local 
gene expression and secretion of pro-inflammatory fac-
tors, especially IL-6 and IL-1β [2], is considered a poten-
tial factor contributing to development of the metabolic 
syndrome [1]. Moreover, it is notable that inflammatory 
signaling molecules including relA (NF-κB p65) and 
MAPK family members [i.e. p44/42 (ERK1/2)] activated 
in adipose tissue during metabolic syndrome, could trig-
ger metaflammation and insulin resistance [3, 4]. It is 
therefore important to determine whether IL-6 or IL-1β 
mediates adipose tissue metaflammation during mac-
rophage infiltration via modulating MAPK or NF-κB 
pathway, to help further elucidate the pathophysiology of 
metabolic syndrome.
Attenuating adipose tissue metaflammation promotes 
insulin sensitivity [5], and might be a potential strategy 
to treat or prevent metabolic syndrome. Accumulated 
evidence suggests that macrophages play a key role in 
influencing the proliferation, survival and differentiation 
of preadipocytes [6–10], which are essential in maintain-
ing adipose tissue homeostasis [11]. Most importantly 
they might even induce or aggravate metaflammation by 
stimulating preadipocytes to express and secrete a vari-
ety of cytokines, most of which are pro-inflammatory 
[12–14]. In vitro studies have shown that 1α,25(OH)2D3 
exerts anti-inflammatory actions on lipopolysaccharide 
(LPS) and macrophage-stimulated adipocytes, by reduc-
ing the release and gene expression of major pro-inflam-
matory factors including IL-6, IL-8 and MCP-1 [15, 16]. 
However, the anti-inflammatory effects of 1α,25(OH)2D3 
on macrophage-stimulated preadipocytes, remains to be 
explored in detail.
In this study, we aimed firstly to test whether IL-6 or 
IL-1β is critical in mediating inflammatory responses 
in MacCM-stimulated preadipocytes, in terms of pro-
inflammatory gene expression and secretion; and sec-
ondly to determine the inflammatory signaling pathways 
activated by examining the phosphorylation of signal-
ing molecules including relA of the NF-κB pathway 
and p44/42 MAPK. Finally, we investigated whether 
1α,25(OH)2D3, could attenuate the inflammatory 
responses in MacCM-stimulated preadipocytes, and 
explored the potential anti-inflammatory mechanisms.
Methods
Preparation of MacCM
The human THP-1 monocytic cell line was kindly pro-
vided by Professor Helen R Griffiths (Aston University, 
UK). Monocytes were cultured in T75 flasks in RPMI-
1640 medium (Sigma-Aldrich, UK) supplemented 
with 10% fetal bovine serum and 100  U/ml penicillin, 
100 μg/ml streptomycin, and incubated at 37  °C in 95% 
air and 5%  CO2. When the monocyte density reached 
1 × 106  cells/ml, the differentiation to pro-inflammatory 
M1 dominant macrophages was induced by 100  nM 
phorbol 12-myristate 13-acetate (Sigma-Aldrich, UK) for 
48 h, and then activated by 1 μg/ml LPS [17] and 1 mM 
ATP (Sigma-Aldrich, UK) for a further 24  h in RPMI-
1640 before medium collection. The MacCM was filtered 
through 0.22 μm filters and stored at − 80 °C.
Culture of human white preadipocytes
Human white preadipocytes derived from subcutaneous 
adipose tissue of a female Caucasian subject (BMI 21; age 
44 years) were obtained from PromoCell (Germany). The 
preadipocytes were cultured in T25 flasks then sub-cul-
tured into 12-well plates (seeding density: 5000 cells per 
 cm2) in preadipocyte growth medium (PromoCell, Ger-
many) supplemented with 100 U/ml penicillin, 100 μg/ml 
streptomycin, and 0.25 μg/ml amphotericin B, and incu-
bated at 37 °C in 95% air and 5%  CO2.
MacCM stimulation and blockade of IL‑6 and IL‑1β action
When confluence was reached, preadipocytes (n = 6 
wells per group) were cultured for 24 h in preadipocyte 
growth medium, which was replaced with 25% MacCM 
(diluted in RPMI-1640) to elicit inflammatory responses, 
together with IL-6 antibody (300, 350 and 450 ng/ml) or 
IL-1β antibody (15 μg/ml as previously established [18]) 
(R&D Systems, UK) to block IL-6 or IL-1β action by neu-
tralization for a further 24 h before cell and supernatant 
collection. Isotype control mouse IgG at the same con-
centrations confirmed that non-specific binding did not 
block inflammatory responses (data not shown). The 
control received a mock treatment of 25% preadipocyte 
growth medium (diluted in RPMI-1640).
MacCM stimulation and 1α,25(OH)2D3 pre‑treatment 
and treatment
When confluence was reached, preadipocytes (n = 6 
wells per group) were pre-treated with 1α,25(OH)2D3 
(ENZO Life Sciences, USA) (reconstituted in DMSO to 
Keywords: Human white preadipocytes, Macrophages, IL-6, IL-1β, Inflammatory responses, relA, p44/42 MAPK, 
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a concentration of 1 μg/μl and diluted to final concentra-
tions of 0.01–10  nM in preadipocyte growth medium). 
The pre-treatment was to boost the potential anti-inflam-
matory effects of 1α,25(OH)2D3 as established previously 
[18]. After 24 h the pre-treatment media were discarded. 
Then, 25% MacCM (diluted in RPMI-1640) was added 
together with 1α,25(OH)2D3 (0.01–10 nM) for a further 
24 h before cell and supernatant collection.
Measurement of inflammatory responses
Cytokine release of the pooled cell supernatants (n = 6) 
were screened by Human Cytokine Array Panel A fol-
lowing the manufacturer’s instructions (R&D Systems, 
UK) and Molecular Imager ChemiDoc XRS+ System 
(Bio-Rad, UK). The results were presented as pixel den-
sity relative to the references of the arrays. The secretion 
levels of major pro-inflammatory factors including IL-1β, 
IL-6, IL-8, MCP-1 and RANTES were measured in dupli-
cate using human ELISA kits following the manufactur-
er’s instructions (R&D Systems, UK) and SPECTROstar 
Nano Microplate Reader (BMG LABTECH, Germany). 
The results were also normalized to total cell protein con-
tent (measured by Thermo Scientific Pierce BCA Protein 
Assay Kit, UK) and presented as μg(cytokine)/mg(cell 
protein). The mRNA levels of IL-1β, IL-6, IL-8, MCP-1 
and RANTES in preadipocytes were measured in dupli-
cate using TaqMan gene expression assays (Applied Bio-
systems, UK), qPCR core kit (Eurogentec, Belgium) and 
Stratagene Mx3005P instrument system. The results were 
normalized to the values of reference gene PPIA [19] and 
presented as fold changes of Ct value relative to controls 
using the  2−ΔΔct formula [20]. The intracellular levels 
(densities) of inflammatory signaling molecules includ-
ing relA, phosphorylated relA, p44/42 MAPK, phospho-
rylated p44/42 MAPK, p38 MAPK and phosphorylated 
p38 MAPK (New England BioLabs, UK) were measured 
using western blotting and Molecular Imager ChemiDoc 
XRS+ System (Bio-Rad, UK). The results were calculated 
as ratios of phosphorylated relA to relA, phosphorylated 
p44/42 MAPK to p44/42 MAPK and phosphorylated 
p38 MAPK to p38 MAPK, normalized to loading control 
vinculin (Abcam, UK), and presented as fold changes of 
density relative to controls. All the antibodies used were 
diluted according to the manufacturer’s instructions. 
Methods of qPCR and western blotting were as previ-
ously described [21].
Statistical analysis
Results are presented as mean ± SEM. For statistical 
analysis, unpaired Student’s t test was used for individual 
group comparisons. One-way ANOVA for independent 
samples was used, followed by Tukey’s test for individual 
group comparisons. A value of p < 0.05 was regarded as 
statistically significant. The analysis and presentation 
were performed using Prism 5 (GraphPad, USA).
Results
IL‑6 and IL‑1β mediate inflammatory responses 
in MacCM‑stimulated preadipocytes
Infiltration of macrophages into adipose tissue induces 
metaflammation [2], which may contribute to meta-
bolic syndrome [1]. In the initial experiments, we 
treated human white preadipocytes with MacCM (25%) 
to elicit inflammatory responses. Cytokine release was 
screened using proteome array and the results revealed 
that (Fig.  1a, b) pro-inflammatory factors including 
IL-6, IL-8, MCP-1 and RANTES were secreted from 
MacCM-stimulated preadipocytes, compared to con-
trols. Surprisingly, IL-1β, which is vital in initiating and 
sustaining metaflammation in adipose tissue [22, 23], was 
not detected. However, (Figs. 1c–g and 2) further ELISA 
results (unnormalized and normalized) show that besides 
IL-6, IL-8, MCP-1 and RANTES, the secretion levels of 
IL-1β were also markedly increased, but relatively lower, 
possibly too low to be detected by the array. In contrast, 
the secretion level of serpin was mildly decreased from 
MacCM-stimulated preadipocytes. Similarly, (Fig.  3) 
the qPCR results show that the mRNA levels of these 
pro-inflammatory factors were generally enhanced in 
MacCM-stimulated preadipocytes, especially IL-1β and 
IL-6, which were approximately 767 and 404-fold higher, 
compared to the control.
The plasma level of IL-6 is almost exclusively deter-
mined by whole-body adiposity and thus closely asso-
ciated with metabolic syndrome [14]. Moreover, IL-6 
has been found to stimulate the synthesis of C-reac-
tive protein, which is  one of the strongest indicators 
of metabolic risk [24]. Hence, we speculated that IL-6 
might mediate inflammatory responses in MacCM-
stimulated preadipocytes. To test this, we blocked IL-6 
action from MacCM-stimulated preadipocytes using 
IL-6 antibody. In preliminary work, a range of IL-6 
antibody doses were tested based on calculations using 
the manufacturer’s instructions, and (Additional file 1: 
Fig. S1PA and S1PB) the results show that 300  ng/ml 
was the optimal dose to inhibit cytokine secretion and 
gene expression. In accordance with this, (Fig.  2) the 
ELISA results (normalized) show that the secretion 
of IL-8 was considerably decreased by IL-6 antibody, 
which was 0.6-fold lower compared with MacCM-stim-
ulated preadipocytes. Likewise, the levels of MCP-1 
and RANTES were moderately decreased by 0.3- and 
0.2-fold, respectively. Although the concentrations of 
IL-1β were numerically lower, this did not reach sta-
tistical significance. The secretion of IL-6 (and IL-1β 
later) is not presented, since additional IL-6 (IL-1β) 
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antibodies in the supernatant will affect the accuracy 
of the ELISA results. Moreover, blocking IL-6 action 
exerted potent inhibitory effects on cytokine gene 
expression, (Fig. 3) as the mRNA levels of IL-1β, IL-6, 
IL-8, MCP-1 and RANTES were all significantly low-
ered by 0.4- to 0.7-fold. Therefore, IL-6 propagates and 
maintains inflammatory responses during adipose tis-
sue metaflammation, since blocking IL-6 action inhib-
its the secretion and gene expression of IL-1β, IL-6, 
IL-8, MCP-1 and RANTES in MacCM-stimulated 
preadipocytes.
A recent study from our group demonstrated that 
IL-1β could target preadipocytes to induce adipose tis-
sue metaflammation [25]. Likewise, the current results 
show that IL-1β is crucial in mediating inflammatory 
responses in macrophage-stimulated preadipocytes, 
(Fig.  2) since by blocking IL-1β action from MacCM-
stimulated preadipocytes with IL-1β antibody (15  μg/
ml), the secretion levels of IL-6 and IL-8 were mod-
erately reduced by 0.5-fold compared with MacCM-
stimulated preadipocytes. However, the release of 
MCP-1 and RANTES were not statistically different 
in the presence of MacCM compared with the con-
trol. In parallel, (Fig. 3) blocking IL-1β action markedly 
decreased the mRNA levels of IL-1β, IL-6, IL-8, MCP-1 
and RANTES by 0.4- to 0.7-fold in MacCM-stimulated 
preadipocytes.
IL‑6 and IL‑1β increase the phosphorylation 
of inflammatory signaling molecules in MacCM‑stimulated 
preadipocytes
A possible mechanism for induction of adipose tissue 
metaflammation is activation of the NF-κB signaling 
pathway via phosphorylation of transcription factor relA 
[5]. In our study, (Fig. 6b) MacCM considerably increased 
the phosphorylation levels of relA by 180%, (Fig.  6a) 
though the levels of NF-κB were similar compared with 
the control. In accordance with that, the NF-κB signaling 
pathway could be activated by IL-1β [5], (Fig.  6b) since 
the decreased phosphorylation levels of relA were signifi-
cantly associated with blocking IL-1β action.
The conventional MAPKs including p44/42 and p38, 
are activated through phosphorylation, and are estab-
lished as playing an important role in various biological 
processes, especially inflammation [26]. Firstly, (Fig.  6a 
and Additional file  2: Fig. S2A) compared to the con-
trol, MacCM had no effect on the levels of p44/42 
MAPK and p38 MAPK. Secondly, (Fig. 6c) the phospho-
rylation of p44/42 MAPK were moderately increased 
by 60% in MacCM-stimulated preadipocytes. In 
Fig. 1 Effects of MacCM on cytokine release from human white preadipocytes. Preadipocytes were either cultured alone (control), or with 
THP-1-MacCM (25%) for 24 h before supernatant collection. a Secreted cytokines were screened by cytokine array. b The results are presented as 
pixel density relative to the reference controls of the arrays. The concentrations of pro-inflammatory factors c IL-1β, d IL-6, e IL-8, f MCP-1 and g 
RANTES were also measured by ELISA. Data are shown as mean ± SEM for groups of 6. The results were analyzed using unpaired Student’s t test and 
confirmed by three independent experiments. A significant difference to control was indicated by ***(p < 0.001)
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parallel, (Additional file 2: Fig. S2B) MacCM remarkably 
increased the phosphorylation of p38 MAPK, which was 
250% higher than observed in the control. Furthermore, 
it is interesting to note that IL-6 triggers inflammatory 
responses by activating the p44/42 MAPK signaling path-
way [27], as indicated by our observation that the phos-
phorylation levels of p44/42 MAPK were significantly 
decreased by blocking IL-6 action in MacCM-stimulated 
preadipocytes (Fig. 6c).
In addition, (Fig.  6c and Additional file  2: Fig. S2B) 
show that after antibody blockade of IL-1β, the phospho-
rylation of p44/42 MAPK and p38 MAPK were slightly 
lower in MacCM-stimulated preadipocytes, but the dif-
ference from control was not statistically significant. 
Likewise, (Fig. 6b and Additional file 2: Fig. S2B) block-
ing IL-6 action did not affect the phosphorylation levels 
of relA or p38 MAPK.
1α,25(OH)2D3 inhibits pro‑inflammatory secretion 
and gene expression in MacCM‑stimulated preadipocytes
We speculated that 1α,25(OH)2D3 might attenu-
ate inflammatory responses in MacCM-stimulated 
preadipocytes, as has previously been demonstrated in 
IL-1β-stimulated preadipocytes [25]. Initially, MacCM-
stimulated preadipocytes were pre-treated and treated 
with 10  nM of 1α,25(OH)2D3 (which was a dose for-
merly established [25]). With respect to pro-inflamma-
tory secretion, (Fig.  2) the ELISA results (normalized) 
show that compared with MacCM-stimulated preadi-
pocytes, 10  nM of 1α,25(OH)2D3 markedly decreased 
the secretion of IL-6 and IL-8 by 0.5- and 0.6-fold, 
whereas the effects to reduce MCP-1 and RANTES 
release were moderate (0.3- and 0.2-fold lower, respec-
tively). However, the secretion of IL-1β was not affected 
in MacCM-stimulated preadipocytes by 10  nM of 
Fig. 2 Effects of 1α,25(OH)2D3 on IL-6 and IL-1β-mediated pro-inflammatory secretion from MacCM-stimulated human white preadipocytes. 
Preadipocytes were either cultured alone (control), or with THP-1-MacCM (25%), or in the presence of IL-6 antibody (300 ng/ml), or IL-1β antibody 
(15 μg/ml) for 24 h. A further group of cells was pre-treated with 1α,25(OH)2D3 (10 nM) for 24 h, followed by treatments with THP-1-MacCM (25%) 
and 1α,25(OH)2D3 (10 nM) for a further 24 h before supernatant collection. The release levels of pro-inflammatory factors a IL-1β, b IL-6, c IL-8, d 
MCP-1 and e RANTES were measured by ELISA and normalized to total cell protein content. Data are shown as mean ± SEM for groups of 6. The 
results were analyzed using one-way ANOVA with Tukey’s post hoc test and confirmed by three independent experiments. A significant difference 
to control was indicated by ***(p < 0.001); to THP-1-MacCM by #(p < 0.05), ##(p < 0.01) and ###(p < 0.001)
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1α,25(OH)2D3. Next, to investigate whether the effects 
of 1α,25(OH)2D3 on the inflammatory responses are 
dose-dependent, we pre-treated and treated MacCM-
stimulated preadipocytes with 0.01 to 1  nM of 
1α,25(OH)2D3 using the same methods. With respect 
to pro-inflammatory secretion, (Fig.  4) firstly, 0.01 to 
1  nM of 1α,25(OH)2D3 did not affect the secretion of 
IL-1β and MCP-1 in MacCM-stimulated preadipo-
cytes. Secondly, only 0.01 nM of 1α,25(OH)2D3 dramat-
ically decreased the secretion levels of IL-6 by 0.7-fold, 
while though numerically lower, no statistically sig-
nificant differences were seen with other doses. Finally, 
relatively high doses of 1α,25(OH)2D3 were significantly 
associated with reduced levels of IL-8 and RANTES, 
as observed that 0.1 and 1 nM of 1α,25(OH)2D3 mildly 
decreased the secretion levels of IL-8 by 0.4-fold and 
RANTES by 0.2-fold, respectively.
In parallel, 1α,25(OH)2D3 exerted complex, but in gen-
eral inhibitory effects on pro-inflammatory gene expres-
sion in MacCM-stimulated preadipocytes. As shown in 
Figs.  3 and 5, 0.01 to 10  nM of 1α,25(OH)2D3 inhibited 
the mRNA levels of IL-1β and RANTES by 0.5- to 0.8-
fold. The mRNA levels of IL-8 were reduced 0.7-fold 
by 1  nM of 1α,25(OH)2D3; other doses had similar but 
moderate inhibitory effects on IL-8 gene expression. The 
mRNA levels of IL-6 were decreased by 0.4- to 0.6-fold, 
by all doses except 0.1 nM of 1α,25(OH)2D3, which had 
no effect. However, only 1 and 10  nM of 1α,25(OH)2D3 
reduced mRNA levels of MCP-1 by 0.7- and 0.5-fold, 
respectively.
Therefore, 1α,25(OH)2D3 attenuates IL-1β and IL-
6-mediated inflammatory responses in MacCM-stim-
ulated preadipocytes. In addition, (Figs.  2, 3) 10  nM 
of 1α,25(OH)2D3 generally reduced pro-inflammatory 
Fig. 3 Effects of 1α,25(OH)2D3 on IL-6 and IL-1β-mediated pro-inflammatory gene expression in MacCM-stimulated human white preadipocytes. 
Preadipocytes were either cultured alone (control), or with THP-1-MacCM (25%), or in the presence of IL-6 antibody (300 ng/ml), or IL-1β antibody 
(15 μg/ml) for 24 h. A further group of cells was pre-treated with 1α,25(OH)2D3 (10 nM) for 24 h, followed by treatments with THP-1-MacCM (25%) 
and 1α,25(OH)2D3 (10 nM) for a further 24 h before cell collection. The mRNA levels of pro-inflammatory factors a IL-1β, b IL-6, c IL-8, d MCP-1 and 
e RANTES were measured by qPCR. Data are shown as mean ± SEM for groups of 6. The results were analyzed using one-way ANOVA with Tukey’s 
post hoc test and confirmed by three independent experiments. A significant difference to control was indicated by ***(p < 0.001); to THP-1-MacCM 
by #(p < 0.05), ##(p < 0.01) and ###(p < 0.001)
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secretion and gene expression, (Figs. 4, 5) but there was 
no consistent dose–response relationship between the 
pro-inflammatory secretion or gene expression and the 
doses of 1α,25(OH)2D3 used in our study.
1α,25(OH)2D3 decreases the phosphorylation of relA 
of the NF‑κB signaling pathway and p44/42 MAPK 
in MacCM‑stimulated preadipocytes
10  nM of 1α,25(OH)2D3 had no effect on the levels of 
relA (Fig.  6a), but moderately decreased the phospho-
rylation levels of relA by 20%, compared to MacCM-
stimulated preadipocytes (Fig.  6b). Similarly, (Fig.  6a) 
the levels of p44/42 MAPK were not affected by 10 nM 
of 1α,25(OH)2D3, but their phosphorylation was reduced 
by 30% (Fig.  6c). Although (Additional file  2: Fig. S2) 
10  nM of 1α,25(OH)2D3 had no effect on the levels 
of p38 MAPK, those of phosphorylated p38 MAPK 
were not affected, either. Additionally, lower doses of 
1α,25(OH)2D3 (0.01 to 1 nM) had no effects on any of the 
above signaling pathways (data not shown).
Overall, 1α,25(OH)2D3 decreases the phosphorylation 
of inflammatory signaling molecules including relA and 
p44/42 MAPK in MacCM-stimulated preadipocytes, 
but only 10 nM of 1α,25(OH)2D3 exerted such effects in 
MacCM-stimulated preadipocytes.
Discussion
The initial results show that in human white preadi-
pocytes, MacCM massively enhanced the secretion 
and gene expression of major pro-inflammatory fac-
tors including IL-1β, IL-6, IL-8, MCP-1 and RANTES, 
which have been measured as indicators of adipose tissue 
metaflammation in keeping with published studies [14, 
24, 28–31]. Although downstream markers of adipose 
Fig. 4 The decreasing effects of 1α,25(OH)2D3 on pro-inflammatory secretion from MacCM-stimulated human white preadipocytes. Preadipocytes 
were either cultured alone (control), or with THP-1-MacCM (25%) for 24 h. Further groups of cells were pre-treated with 1α,25(OH)2D3 (0.01–10 nM) 
for 24 h, followed by treatments with THP-1-MacCM (25%) and 1α,25(OH)2D3 (0.01–10 nM) for a further 24 h before supernatant collection. The 
concentrations of pro-inflammatory factors a IL-1β, b IL-6, c IL-8, d MCP-1 and e RANTES were measured by ELISA and normalized to total cell 
protein content. Data are shown as mean ± SEM for groups of 6. The results were analyzed using one-way ANOVA with Tukey’s post hoc test and 
confirmed by three independent experiments. A significant difference to control was indicated by ***(p < 0.001); to THP-1-MacCM by #(p < 0.05), 
##(p < 0.01) and ###(p < 0.001)
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tissue inflammation such as leptin and adiponectin are 
of interest [32], these adipokines are usually secreted by 
mature adipocytes; preadipocytes express and secrete 
extremely low levels of adiponectin and leptin, which we 
did test in this study (data not shown). Interestingly, we 
also found that TNF-α, one of the major pro-inflamma-
tory factors released from adipocytes in metaflammation 
[4], was not secreted at detectable levels from MacCM-
stimulated preadipocytes. Hence, it appears that preadi-
pocytes have a unique secretome compared to mature 
adipocytes during metaflammation.
Considered as an adipokine [14], IL-6 is also a multifac-
eted, pleiotropic cytokine and suggested to play a central 
role in the development of metabolic syndrome by induc-
ing metaflammation and insulin resistance [33]. Hence, 
rather than neutralizing IL-1β in MacCM as formally 
established [18], we blocked IL-6 and IL-1β action dur-
ing the stimulation, to determine whether either of them 
could mediate the inflammatory responses in MacCM-
stimulated preadipocytes. The present study showed 
that both IL-6 and IL-1β mediate MacCM-stimulated 
inflammatory responses in preadipocytes by increasing 
the phosphorylation of relA of the NF-κB pathway and 
p44/42 MAPK, respectively. Moreover, it might be sug-
gested that IL-6 exerts broader inflammatory effects on 
preadipocytes, for most of the pro-inflammatory fac-
tors (though not IL-1β) were inhibited when IL-6 action 
was blocked, whilst the chemoattractants MCP-1 and 
RANTES were not significantly reduced by IL-1β block-
ade. However, it is clear that IL-1β is also important as 
its blockade did significantly attenuate the inflammatory 
responses.
Intriguingly, our results suggest that 1α,25(OH)2D3 
could attenuate inflammatory responses in mac-
rophage-stimulated preadipocytes during adipose tis-
sue metaflammation, for 1α,25(OH)2D3 significantly 
Fig. 5 The decreasing effects of 1α,25(OH)2D3 on pro-inflammatory gene expression in MacCM-stimulated human white preadipocytes. 
Preadipocytes were either cultured alone (control), or with THP-1-MacCM (25%) for 24 h. Further groups of cells were pre-treated with 1α,25(OH)2D3 
(0.01–10 nM) for 24 h, followed by treatments with THP-1-MacCM (25%) and 1α,25(OH)2D3 (0.01–10 nM) for a further 24 h before cell collection. 
The mRNA levels of pro-inflammatory factors a IL-1β, b IL-6, c IL-8, d MCP-1 and e RANTES were measured from cells by qPCR. Data are shown as 
mean ± SEM for groups of 6. The results were analyzed using one-way ANOVA with Tukey’s post hoc test and confirmed by three independent 
experiments. A significant difference to control was indicated by ***(p < 0.001); to THP-1-MacCM by #(p < 0.05), ##(p < 0.01) and ###(p < 0.001)
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inhibited pro-inflammatory secretion from MacCM-
stimulated preadipocytes. Furthermore, 1α,25(OH)2D3 
inhibits the mRNA of the major pro-inflammatory 
factors in MacCM-stimulated preadipocytes probably 
by decreasing phosphorylation of relA, which is con-
sistent with other relevant studies that phosphorylated 
Fig. 6 Modifying effects of IL-6, IL-1β and 1α,25(OH)2D3 on the phosphorylation of relA and p44/42 MAPK in MacCM-stimulated human white 
preadipocytes. Preadipocytes were either cultured alone (control), or with THP-1-MacCM (25%), or in the presence of IL-6 antibody (300 ng/ml), 
or IL-1β antibody (15 μg/ml) for 24 h. A further group of cells was pre-treated with 1α,25(OH)2D3 (10 nM) for 24 h, followed by treatments with 
THP-1-MacCM (25%) and 1α,25(OH)2D3 (10 nM) for a further 24 h before lysate collection. a The levels of relA, phosphorylated relA, p44/42 MAPK 
and phosphorylated p44/42 MAPK were measured by western blotting. The results are presented as fold changes of ratios of b phosphorylated 
relA to relA, c phosphorylated p44/42 MAPK to p44/42 MAPK to controls. Data are shown as mean ± SEM for groups of 6. The results were analyzed 
using one-way ANOVA with Tukey’s post hoc test and confirmed by three independent experiments. A significant difference to control was 
indicated by ***(p < 0.001); to THP-1-MacCM by #(p < 0.05), ##(p < 0.01) and ###(p < 0.001)
Fig. 7 1α,25(OH)2D3 attenuates Il-6 and IL-1β-mediated inflammatory responses in MacCM-stimulated human white preadipocytes. Accumulated 
macrophages infiltrating into white adipose tissue induce metaflammation, which is embodied by inflammatory responses including increased 
local gene expression and secretion of pro-inflammatory factors, particularly IL-1β, IL-6, IL-8, MCP-1 and RANTES. Among these pro-inflammatory 
factors, by binding to its receptor, IL-1β initiates and sustains the inflammatory responses in macrophage-stimulated preadipocytes by enhancing 
the phosphorylation of relA of the NF-κB signaling pathway, while in the same ligand-receptor manner IL-6 mediates similar responses by 
enhancing the phosphorylation of p44/42 MAPK. Besides directly inhibiting the pro-inflammatory gene expression (not tested in our study), 
1α,25(OH)2D3 attenuates IL-1β-mediated inflammatory responses by decreasing the phosphorylation of relA in the nucleus. Moreover, 1α,25(OH)2D3 
can exert a non-genomic action by decreasing the phosphorylation of p44/42 MAPK in the cytoplasm, to attenuate IL-6-mediated inflammatory 
responses
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(activated) relA enhances the expression of pro-inflam-
matory genes including IL-1β, IL-6 and MCP-1 [34]. 
It is also possible that 1α,25(OH)2D3 could inhibit 
pro-inflammatory gene expression by antagonizing 
the action of relA in the nucleus [35, 36]. Besides the 
genomic effects, 1α,25(OH)2D3 can exert non-genomic 
actions in the cytoplasm by modulating the MAPK 
pathways [37], which we also found, as 1α,25(OH)2D3 
might inhibit the pro-inflammatory responses by 
reducing p44/42 MAPK phosphorylation in MacCM-
stimulated preadipocytes. Possible limitations of our 
study are that we did not test whether 1α,25(OH)2D3 
could directly modulate the pro-inflammatory gene 
expression in the nucleus by chromatin immunopre-
cipitation, as 1α,25(OH)2D3 inhibits the expression 
of genes including IL-2, IL-12, TNF-α, IFN-γ, GM-
CSF, which are important in attenuating inflammatory 
responses in various tissues [38–41]. In addition, since 
the anti-inflammatory properties of 1α,25(OH)2D3 
could be exerted in MacCM-stimulated preadipocytes 
in single or multiple above-mentioned manners (Fig. 7), 
which might explain why there was no obvious dose–
response relationship between 1α,25(OH)2D3 and the 
pro-inflammatory secretion or gene expression.
A body of evidence has revealed that metaflamma-
tion might be a critical link between metabolic syndrome 
and cardiovascular disease [42]. Our results suggest that 
vitamin D might be an independent protective factor to 
cardiovascular risk due to its anti-inflammatory proper-
ties, and given that it also influences several phases of the 
atherosclerotic process, especially influencing vascular 
remodeling and atherothrombosis [43]. Moreover, given 
the benefits of canakinumab seen in the CANTOS trial 
[44], along with the present findings, IL-1β blocker and 
1α,25(OH)2D3 might complete each other to attenuate 
metaflammation in adipose tissue, thus to potentially help 
prevent metabolic syndrome and subsequent cardiovascu-
lar disease.
Conclusions
1α,25(OH)2D3 attenuates IL-6 and IL-1β-mediated inflam-
matory responses, probably by inhibiting p44/42 and relA 
phosphorylation in MacCM-stimulated human white 
preadipocytes.
Additional files
Additional file 1: Figure S1. IL-6 antibodies block inflammatory 
responses in MacCM-stimulated human white preadipocytes. Preadipo-
cytes were either cultured alone (control), with THP-1-MacCM (25%), or 
in the presence of IL-6 antibody (300, 350 and 450 ng/ml) for 24 h before 
supernatant and cell collection. (Panel A) The release levels of pro-inflam-
matory factors (A) IL-1β, (B) IL-8, (C) MCP-1 and (D) RANTES were measured 
by ELISA and normalized to total cell protein content. (Panel B) The mRNA 
levels of pro-inflammatory factors (A) IL-1β, (B) IL-6, (C) IL-8, (D) MCP-1 and 
(E) RANTES were measured by qPCR. Data are shown as means ± SEM for 
groups of 6. The results were analyzed using one-way ANOVA with Tukey’s 
post hoc test and confirmed by three independent experiments. A signifi-
cant difference to control was indicated by ***(p<0.001); to THP-1-MacCM 
by #(p<0.05), ##(p<0.01) and ###(p<0.001).
Additional file 2: Figure S2. Modifying effect of MacCM on the phospho-
rylation of p38 MAPK in human white preadipocytes. Preadipocytes were 
either cultured alone (control), with THP-1-MacCM (25%), or in the pres-
ence of IL-6 antibody (300 ng/ml), or IL-1β antibody (15 μg/ml) for 24 h. A 
further group of cells was pre-treated with 1α,25(OH)2D3 (10 nM) for 24 h, 
followed by treatments with THP-1-MacCM (25%) and 1α,25(OH)2D3 (10 
nM) for a further 24 h before lysate collection. The p38 MAPK and phos-
phorylated p38 MAPK were measured by western blotting. The results are 
presented as fold changes of ratios of phosphorylated 38 MAPK to p38 
MAPK to controls. Data are shown as means ± SEM for groups of 6. The 
results were analyzed using one-way ANOVA with Tukey’s post hoc test 
and confirmed by three independent experiments. A significant difference 
to control was indicated by ***(p<0.001).
Abbreviations
MAPK: mitogen-activated protein kinase; IL: interleukin; MacCM: macrophage 
conditioned medium; MCP-1: monocyte chemoattractant protein-1; RANTES: 
regulated on activation, normal T cell expressed and secreted; LPS: lipopoly-
saccharide; ATP: adenosine triphosphate.
Authors’ contributions
CB and JZ conceived the study. JZ performed the experiments and analyzed 
the results. JW and CB supervised the findings of this study. JW and JZ 
discussed the results and contributed to the final manuscript. All authors read 
and approved the final manuscript.
Author details
1 Institute of Ageing and Chronic Disease, William Henry Duncan Building, Uni-
versity of Liverpool, 6 West Derby Street, Liverpool L7 8TX, UK. 2 Department 
of Endocrinology and Metabolism, The Second Affiliated Hospital of Soochow 
University, 1055 Sanxiang Road, Gusu District, Suzhou 215004, People’s Repub-
lic of China. 3 Clinical Science Center, University Hospital Aintree, Longmoor 




The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analyzed during this study are included in this published 
article [and its additional information files].
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Funding
This work was supported by the China Scholarship Council, with a grant 
awarded to Jingjing Zhu (No. 201306920002).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 12 October 2018   Accepted: 18 January 2019
Page 11 of 12Zhu et al. Diabetol Metab Syndr            (2019) 11:9 
References
 1. Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North 
Am. 2014;43(1):1–23.
 2. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu 
Rev Immunol. 2011;29:415–45.
 3. Watt MJ, Hevener A, Lancaster GI, Febbraio MA. Ciliary neurotrophic 
factor prevents acute lipid-induced insulin resistance by attenuating 
ceramide accumulation and phosphorylation of c-Jun N-terminal kinase 
in peripheral tissues. Endocrinology. 2006;147(5):2077–85.
 4. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 
2006;444(7121):860–7.
 5. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J 
Clin Investig. 2006;116(7):1793–801.
 6. Neese RA, Misell LM, Turner S, Chu A, Kim J, Cesar D, et al. Measure-
ment in vivo of proliferation rates of slow turnover cells by 2H2O 
labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci USA. 
2002;99(24):15345–50.
 7. Maumus M, Sengenes C, Decaunes P, Zakaroff-Girard A, Bourlier V, 
Lafontan M, et al. Evidence of in situ proliferation of adult adipose tissue-
derived progenitor cells: influence of fat mass microenvironment and 
growth. J Clin Endocrinol Metab. 2008;93(10):4098–106.
 8. Molgat AS, Gagnon A, Foster C, Sorisky A. The activation state of 
macrophages alters their ability to suppress preadipocyte apoptosis. J 
Endocrinol. 2012;214(1):21–9.
 9. Molgat AS, Gagnon A, Sorisky A. Preadipocyte apoptosis is prevented by 
macrophage-conditioned medium in a PDGF-dependent manner. Am J 
Physiol Cell Physiol. 2009;296(4):C757–65.
 10. Constant VA, Gagnon A, Landry A, Sorisky A. Macrophage-conditioned 
medium inhibits the differentiation of 3T3-L1 and human abdominal 
preadipocytes. Diabetologia. 2006;49(6):1402–11.
 11. Sorisky A, Molgat AS, Gagnon A. Macrophage-induced adipose tissue 
dysfunction and the preadipocyte: should I stay (and differentiate) or 
should I go? Adv Nutr. 2013;4(1):67–75.
 12. Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, Penicaud L, et al. 
Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol 
Chem. 2003;278(11):9850–5.
 13. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW 
Jr. Obesity is associated with macrophage accumulation in adipose tis-
sue. J Clin Investig. 2003;112(12):1796–808.
 14. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bohm M, 
et al. Interleukin-6 induces oxidative stress and endothelial dysfunc-
tion by overexpression of the angiotensin II type 1 receptor. Circ Res. 
2004;94(4):534–41.
 15. Ding C, Wilding JP, Bing C. 1,25-dihydroxyvitamin D3 protects against 
macrophage-induced activation of NFkappaB and MAPK signalling and 
chemokine release in human adipocytes. PLoS ONE. 2013;8(4):e61707.
 16. Lira FS, Rosa JC, Cunha CA, Ribeiro EB, do Nascimento CO, Oyama LM, 
et al. Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in 
high fat diet decrease IL-6 production in murine epididymal adipose 
tissue and 3T3-L1 adipocytes following LPS stimulation. Lipids Health Dis. 
2011;10:37.
 17. Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg 
E, et al. Human IL-23-producing type 1 macrophages promote but IL-
10-producing type 2 macrophages subvert immunity to (myco)bacteria. 
Proc Natl Acad Sci USA. 2004;101(13):4560–5.
 18. Gao D, Trayhurn P, Bing C. 1,25-Dihydroxyvitamin D3 inhibits the 
cytokine-induced secretion of MCP-1 and reduces monocyte recruitment 
by human preadipocytes. Int J Obes (Lond). 2013;37(3):357–65.
 19. Feroze-Merzoug F, Berquin IM, Dey J, Chen YQ. Peptidylprolyl isomerase 
A (PPIA) as a preferred internal control over GAPDH and beta-actin in 
quantitative RNA analyses. BioTech. 2002;32(4):776–8, 80, 82.
 20. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the compara-
tive C(T) method. Nat Protoc. 2008;3(6):1101–8.
 21. Ding C, Wilding JP, Bing C. Vitamin D3 analogues ZK159222 and Zk191784 
have anti-inflammatory properties in human adipocytes. Endocrinol 
Metab Genet. 2016;1:1–8.
 22. Koenen TB, Stienstra R, van Tits LJ, Joosten LA, van Velzen JF, Hijmans A, 
et al. The inflammasome and caspase-1 activation: a new mechanism 
underlying increased inflammatory activity in human visceral adipose 
tissue. Endocrinology. 2011;152(10):3769–78.
 23. McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, Mills KH, 
et al. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat 
diet-induced adipose tissue inflammation coincident with improved 
glucose homeostasis. Diabetes. 2011;60(6):1688–98.
 24. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich 
PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the 
synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 
1988;232(2):347–50.
 25. Zhu J, Bing C, Wilding JPH. Vitamin D receptor ligands attenuate the 
inflammatory profile of IL-1beta-stimulated human white preadipocytes 
via modulating the NF-kappaB and unfolded protein response path-
ways. Biochem Biophys Res Commun. 2018. https ://doi.org/10.1016/j.
bbrc.2018.06.115.
 26. Cargnello M, Roux PP. Activation and function of the MAPKs and their 
substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 
MMBR. 2011;75(1):50–83.
 27. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor 
system and its role in physiological and pathological conditions. Clin Sci. 
2012;122(4):143–59.
 28. Elgazar-Carmon V, Rudich A, Hadad N, Levy R. Neutrophils transiently 
infiltrate intra-abdominal fat early in the course of high-fat feeding. J 
Lipid Res. 2008;49(9):1894–903.
 29. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, et al. 
CCR2 modulates inflammatory and metabolic effects of high-fat feeding. 
J Clin Investig. 2006;116(1):115–24.
 30. Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, et al. Circulat-
ing levels of MCP-1 and IL-8 are elevated in human obese subjects 
and associated with obesity-related parameters. Int J Obes (Lond). 
2006;30(9):1347–55.
 31. Kitade H, Sawamoto K, Nagashimada M, Inoue H, Yamamoto Y, Sai Y, et al. 
CCR5 plays a critical role in obesity-induced adipose tissue inflammation 
and insulin resistance by regulating both macrophage recruitment and 
M1/M2 status. Diabetes. 2012;61(7):1680–90.
 32. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin 
Immunol. 2005;115(5):911–9 (quiz 20).
 33. Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator 
interleukin-6 and obesity. Inflam Res. 2009;58(11):727–36.
 34. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R, et al. Weight 
loss and lipolysis promote a dynamic immune response in murine adi-
pose tissue. J Clin Investig. 2010;120(10):3466–79.
 35. Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ. 1alpha,25-dihydrox-
yvitamin D3 and a variety of its natural metabolites transcriptionally 
repress nuclear-factor-kappaB-mediated interleukin-8 gene expression. 
Eur J Biochem. 1997;250(1):63–71.
 36. Alroy I, Towers TL, Freedman LP. Transcriptional repression of the 
interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 
complex formation by a nuclear hormone receptor. Mol Cell Biol. 
1995;15(10):5789–99.
 37. Doroudi M, Schwartz Z, Boyan BD. Membrane-mediated actions of 
1,25-dihydroxy vitamin D3: a review of the roles of phospholipase A2 
activating protein and Ca(2+)/calmodulin-dependent protein kinase II. J 
Steroid Biochem Mol Biol. 2015;147:81–4.
 38. D’Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, 
et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involve-
ment of NF-kappaB downregulation in transcriptional repression of the 
p40 gene. J Clin Investig. 1998;101(1):252–62.
 39. Muller K, Bendtzen K. 1,25-Dihydroxyvitamin D3 as a natural regula-
tor of human immune functions. J Investig Dermatol Symp Proc. 
1996;1(1):68–71.
 40. Tobler A, Gasson J, Reichel H, Norman AW, Koeffler HP. Granulocyte-
macrophage colony-stimulating factor. Sensitive and receptor-mediated 
regulation by 1,25-dihydroxyvitamin D3 in normal human peripheral 
blood lymphocytes. J Clin Investig. 1987;79(6):1700–5.
 41. Manolagas SC, Provvedini DM, Tsoukas CD. Interactions of 1,25-dihy-
droxyvitamin D3 and the immune system. Mol Cell Endocrinol. 
1985;43(2–3):113–22.
Page 12 of 12Zhu et al. Diabetol Metab Syndr            (2019) 11:9 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 42. Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J. Metabolic syndrome 
and cardiovascular disease. Ann Clin Biochem. 2007;44(Pt 3):232–63.
 43. Iannuzzo G, Forte F, Lupoli R, Di Minno MND. Association of Vitamin D 
deficiency with peripheral arterial disease: a meta-analysis of literature 
studies. J Clin Endocrinol Metab. 2018. https ://doi.org/10.1210/jc.2018-
00136 .
 44. Baylis RA, Gomez D, Mallat Z, Pasterkamp G, Owens GK. The CANTOS trial: 
one important step for clinical cardiology but a giant leap for vascular 
biology. Arterioscler Thromb Vasc Biol. 2017;37(11):e174–7.
